MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement in Ontario under the province’s new Funding Accelerated for Specific Treatments (FAST) program, specifically targeting newly diagnosed chronic myeloid leukemia (CML) patients. This announcement, made by Novartis Canada, highlights a major shift in how innovative cancer therapies reach patients faster through targeted provincial health policy efforts. Scemblix®’s inclusion in the FAST program follows its expanded regulatory approvals in Canada and builds on ongoing efforts to reduce wait times for access to breakthrough cancer treatments.

Science Significance

Scemblix® (asciminib) represents a scientifically innovative approach to treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Unlike traditional tyrosine kinase inhibitors (TKIs) that compete at the ATP binding site, asciminib functions as a STAMP inhibitor, engaging a unique allosteric target that enhances molecular response and tolerability in patients. Its expanded approval for newly diagnosed and previously treated Ph+ CML reflects robust clinical evidence showing superior efficacy and favorable safety compared with standard care options. This mechanism delivers a precision oncology therapy that aligns with evolving scientific paradigms in targeted cancer treatment and positions Scemblix® as a next-generation option in the leukemia care landscape.

Regulatory Significance

The Ontario FAST program operates within a broader regulatory environment that includes Health Canada’s Notice of Compliance for Scemblix® and the use of accelerated pathways such as Project Orbis for timely review and approval of promising oncology agents. Prioritizing Scemblix® for public reimbursement under FAST effectively bridges the gap between regulatory approval and patient access by enabling funding decisions to occur concurrently with or soon after Health Canada’s authorization. This approach reflects regulatory innovation that aims to expedite access to confirmed safe and effective therapies while maintaining rigorous oversight. The FAST initiative, as a provincial policy, amplifies regulatory achievements by enabling earlier reimbursement decisions and aligning them with demonstrated clinical value.

Business Significance

For Novartis, Scemblix®’s priority placement under the FAST program enhances the commercial trajectory of a leading CML therapy in Canada. This decision supports broader market access and may accelerate uptake among healthcare providers and patients by minimizing financial barriers and delays associated with traditional reimbursement negotiations. The visibility and momentum generated by FAST prioritization can strengthen Novartis’ position in the oncology market and potentially influence payer policies beyond Ontario, encouraging other provinces or national bodies to consider similar accelerated access models. Early reimbursement can also support patient support program engagement and bolster overall confidence in Scemblix® as a standard of care for Ph+ CML.

Patients’ Significance

For patients living with chronic myeloid leukemia, timely access to effective treatment can be life-altering. CML, a blood cancer marked by the presence of the Philadelphia chromosome, often requires continuous therapy to maintain disease control. By qualifying for priority access under FAST, eligible Ontarians can potentially begin Scemblix® sooner, reducing anxiety and uncertainty associated with waiting for reimbursement decisions. Advocacy groups have underscored the urgency of getting breakthrough treatments into patients’ hands, reflecting the real-world impact that accelerated funding models can have on patient outcomes and quality of life. Earlier access means patients may start personalized cancer therapy without prolonged delays, which can be critical in chronic and progressive disease settings such as Ph+ CML.

Policy Significance

The FAST program marks a transformative policy shift in Ontario’s healthcare landscape, aimed at addressing systemic delays in drug funding decisions. Traditional reimbursement pathways can extend timelines by a year or more after regulatory approval, but FAST seeks to reduce these gaps by prioritizing high-impact treatments, especially in oncology. By design, FAST will expedite access to a set number of high-priority drugs annually, potentially serving as a model for other jurisdictions across Canada and internationally. Policy experts note that linking regulatory approval, accelerated pathways like Project Orbis, and provincial reimbursement mechanisms represents a new blueprint for efficient, patient-centered drug access. As jurisdictions grapple with balancing cost, clinical benefit, and access equity, FAST’s early success with Scemblix® could inform future health policy reforms.

Scemblix®’s prioritization under Ontario’s FAST program signifies a meaningful step forward in bridging the gap between pharmaceutical innovation and patient access, reinforcing the importance of adaptive health policy in delivering timely care. For Novartis Canada, healthcare providers, and especially patients with Ph+ CML, the move underscores the collective value of regulatory agility, scientific advancement, and policy leadership in oncology. As FAST progresses, the implications for accelerated drug access may extend well beyond Ontario, shaping the future of public reimbursement strategies and reinforcing the critical role of innovative therapies in modern cancer treatment.

Source:  Novartis press release